MedTrace Logo

Total Hip Arthroplasty: Multiple Blocks by UltraSound

NCT01276925 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 81

Last updated 2015-10-23

No results posted yet for this study

Summary

Patients undergoing total hip arthroplasty may experience severe postoperative pain. This is normally treated with opioids, which can cause side effects such as nausea, vomiting, obstipation and sedation. The hypothesis is that patients receiving peripheral nerve blockade of three nerves leading pain stimuli from the hip will experience less pain, will consume less opioid and therefore have less side effects, and will be mobilized more quickly than patients not receiving the peripheral nerve blockade.

Conditions

  • Pain, Postoperative

Interventions

DRUG

Ropivacaine

7,5 mg/ml. 10 ml for the femoral nerve, 10 ml for the anterior division of the obturator nerve, 5 ml for the lateral femoral cutaneous nerve.

DRUG

Ropivacaine

7,5 mg/ml. 10 ml for the anterior division of the obturator nerve, 5 ml for the lateral femoral cutaneous nerve.

DEVICE

Ultrasound

All nerve blockades will be performed with ultrasound guidance.

PROCEDURE

Peripheral nerve blockade

All patients will receive injections around the three nerves before surgery.

DRUG

Saline

Isotonic. 10 ml for the femoral nerve.

PROCEDURE

Total hip arthroplasty

All patients undergoes total hip arthroplasty.

DRUG

Bupivacaine

5 mg/ml. 3 ml for spinal anaesthesia.

Sponsors & Collaborators

  • Bispebjerg Hospital

    lead OTHER

Principal Investigators

  • Birgitte M Krogh, MD · Bispebjerg Hospital

  • Kenneth Jensen, MD · Bispebjerg Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-08-31
Primary Completion
2016-05-31
Completion
2016-05-31

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01276925 on ClinicalTrials.gov